医学不能手术的中心型早期非小细胞肺癌立体定向放疗总生存列线图的开发与外部验证
基于220例接受SBRT的中心型早期NSCLC患者构建预测6个月、1年、2年和3年总生存的列线图,纳入PTV、年龄、WHO体能状态、肿瘤肺叶位置和超中心位置5个变量,校正C-index为0.64(95%CI 0.59-0.69),外部验证C-index为0.62(95%CI 0.61-0.64),校准图显示预测准确性良好。
要点
- 列线图包含PTV、年龄、WHO PS、肿瘤肺叶位置和超中心位置5个变量。
- 建模队列校正C-index为0.64(95%CI 0.59-0.69),区分能力中等。
- 外部验证C-index为0.62(95%CI 0.61-0.64),校准图显示预测准确性良好。
核心结论
- 开发并外部验证了首个用于预测中心型早期NSCLC患者SBRT后总生存概率的列线图。
研究设计与样本
- 回顾性识别接受SBRT的中心型NSCLC患者,获取基线特征,基于Cox比例风险模型构建列线图,采用bootstrap采样验证模型构建过程,并在另一中心接受SBRT的中心型NSCLC患者队列中进行外部验证。
主要发现
- 列线图基于220例患者数据构建,包含PTV、年龄、WHO体能状态、肿瘤肺叶位置和超中心位置5个变量。
- 列线图校正乐观度后的C-index为0.64(95%CI 0.59-0.69),区分能力中等。
- 校准图显示预测准确性良好。
- 外部验证C-index为0.62(95%CI 0.61-0.64),显示可接受的效度。
临床怎么用
- 该列线图基于5个患者和肿瘤特征,可为中心型早期NSCLC接受SBRT的患者提供个体化生存预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Current nomograms predicting survival prognosis after stereotactic body radiation therapy (SBRT) in non-small cell lung cancer (NSCLC) are based on peripherally located tumors. However, patients with a central lung tumor tend to be older, the tumor is often larger and fraction-schedules are risk-adapted. Therefore, we developed and externally validated a nomogram to predict overall survival (OS) in patients having centrally located early-stage NSCLC treated with SBRT. MATERIALS AND METHODS: Patients who underwent SBRT for centrally located NSCLC were identified and baseline characteristics were obtained. A nomogram was built to predict 6-month, 1-, 2- and 3-year OS using Cox proportional hazards model. The model building procedure was validated using bootstrap sampling. To determine generalizability, external validation was performed on a cohort of patients with central NSCLC treated with SBRT from another center. Discriminatory ability was measured with the concordance index (C-index) and calibration plots were used to compare Kaplan-Meier-estimated and nomogram-predicted OS. RESULTS: The nomogram was built on data of 220 patients and consisted of the following variables: PTV, age, WHO performance status, tumor lobe location and ultracentral location. The C-index of the nomogram (corrected for optimism) was moderate at 0.64 (95% confidence interval (CI) 0.59-0.69). Calibration plots showed favorable predictive accuracy. The external validation showed acceptable validity with a C-index of 0.62 (95% CI 0.61-0.64). DISCUSSION: We developed and externally validated the first nomogram to estimate the OS-probability in patients with centrally located NSCLC treated with SBRT. This nomogram is based on 5 patient and tumor characteristics and gives an individualized survival prediction.
引用
- Duijm M, Oomen-de Hoop E, van Voort van der Zyp N, et al. The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma. Radiother Oncol. 2021. PMID: 33418006. doi:10.1016/j.radonc.2020.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。